Andrew J Morris Selected Research

Ascites

9/2003	Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.
3/2003	The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrew J Morris Research Topics

Disease

24	Inflammation (Inflammations) 01/2023 - 10/2005
21	Neoplasms (Cancer) 05/2023 - 03/2003
15	Atherosclerosis 02/2024 - 04/2009
14	Obesity 02/2024 - 08/2011
13	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 08/2008
7	Insulin Resistance 01/2021 - 04/2012
7	Coronary Artery Disease (Coronary Atherosclerosis) 01/2020 - 03/2014
6	Neoplasm Metastasis (Metastasis) 05/2023 - 03/2009
5	Ovarian Neoplasms (Ovarian Cancer) 06/2012 - 03/2003
4	Wounds and Injuries (Trauma) 12/2023 - 08/2013
4	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 03/2012
4	Weight Loss (Weight Reduction) 08/2019 - 01/2013
4	Body Weight (Weight, Body) 08/2019 - 11/2015
4	Vascular System Injuries 01/2019 - 09/2008
3	Atherosclerotic Plaque (Atheroma) 02/2024 - 10/2003
3	Breast Neoplasms (Breast Cancer) 05/2023 - 09/2013
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 02/2023 - 01/2017
3	Type 2 Diabetes Mellitus (MODY) 02/2023 - 04/2012
3	Non-alcoholic Fatty Liver Disease 02/2023 - 02/2019
3	Metabolic Diseases (Metabolic Disease) 02/2023 - 03/2017
3	Fatty Liver 01/2023 - 12/2017
3	Myocardial Infarction 01/2023 - 06/2013
3	Sepsis (Septicemia) 01/2021 - 01/2013
3	Mental Disorders (Mental Disorder) 11/2020 - 01/2016
2	Traumatic Brain Injuries (Traumatic Brain Injury) 07/2023 - 02/2014
2	Hyperlipidemias (Hyperlipidemia) 12/2021 - 11/2019
2	Hemorrhage 01/2021 - 03/2009
2	Thrombocytopenia (Thrombopenia) 01/2021 - 01/2013
2	Glucose Intolerance 06/2020 - 01/2019
2	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2019 - 09/2013
2	Mitochondrial Diseases (Mitochondrial Disease) 02/2019 - 01/2018
2	Fibrosis (Cirrhosis) 01/2019 - 12/2017
2	Colonic Neoplasms (Colon Cancer) 09/2017 - 01/2011
2	Cardiotoxicity 11/2015 - 11/2015
2	Asthma (Bronchial Asthma) 04/2015 - 10/2013
2	Hyperplasia 01/2013 - 04/2009
2	Thrombosis (Thrombus) 01/2012 - 03/2009
2	Ascites 09/2003 - 03/2003
1	Dental Caries (Decay, Dental) 05/2024

Drug/Important Bio-Agent (IBA)

26	LipidsIBA 02/2023 - 03/2003
20	lysophosphatidic acidIBA 01/2022 - 03/2003
10	EnzymesIBA 01/2020 - 03/2003
9	Lysophosphatidic Acid ReceptorsIBA 01/2022 - 08/2008
8	Proteins (Proteins, Gene)FDA Link 01/2021 - 10/2003
7	Glucose (Dextrose)FDA LinkGeneric 02/2023 - 01/2013
7	Phosphotransferases (Kinase)IBA 01/2023 - 04/2010
7	Phosphates (Orthophosphate)IBA 01/2023 - 03/2003
7	Polychlorinated Biphenyls (PCBs)IBA 01/2022 - 02/2011
7	lipid phosphate phosphataseIBA 01/2022 - 09/2003
6	Biomarkers (Surrogate Marker)IBA 07/2023 - 01/2012
6	LysophospholipidsIBA 07/2023 - 01/2012
6	3,4,5,3',4'-pentachlorobiphenylIBA 12/2020 - 12/2017
6	Fatty Acids (Saturated Fatty Acids)IBA 01/2019 - 06/2012
6	SphingolipidsIBA 01/2019 - 04/2012
5	CeramidesIBA 12/2021 - 03/2003
5	Phospholipids (Phosphatides)FDA LinkGeneric 11/2020 - 03/2014
4	LDL Receptors (LDL Receptor)IBA 01/2020 - 01/2018
4	trimethyloxamine (trimethylamine N-oxide)IBA 12/2019 - 01/2016
4	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 01/2019 - 01/2012
4	Environmental Pollutants (Pollutants, Environmental)IBA 01/2019 - 02/2016
4	LigandsIBA 01/2019 - 06/2010
4	SphingosineIBA 01/2019 - 03/2003
3	CholesterolIBA 02/2024 - 01/2019
3	NexusIBA 12/2020 - 03/2014
3	DioxinsIBA 06/2020 - 01/2018
3	Transcription Factors (Transcription Factor)IBA 12/2019 - 01/2019
3	oxidized low density lipoproteinIBA 11/2019 - 04/2010
3	CytokinesIBA 08/2019 - 01/2013
3	Messenger RNA (mRNA)IBA 01/2019 - 09/2003
3	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 01/2019 - 10/2015
3	Fatty Acid Synthases (Fatty Acid Synthase)IBA 01/2019 - 03/2012
3	3,4,3',4'-tetrachlorobiphenylIBA 01/2019 - 01/2013
3	Insulin (Novolin)FDA Link 10/2018 - 05/2013
3	IntegrinsIBA 02/2014 - 03/2009
3	Phospholipase DIBA 02/2011 - 10/2003
2	NeurotensinIBA 02/2024 - 01/2016
2	BilirubinIBA 02/2023 - 01/2023
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2023 - 11/2019
2	Complement System Proteins (Complement)IBA 01/2022 - 01/2019
2	Persistent Organic PollutantsIBA 01/2022 - 01/2018
2	mirabegronIBA 01/2021 - 01/2020
2	Inulin FDA Link 06/2020 - 01/2020
2	AntibodiesIBA 01/2020 - 02/2014
2	Choline (Choline Chloride)IBA 01/2020 - 02/2019
2	1-dodecylpyridoxal (PLD)IBA 01/2020 - 03/2009
2	TVB-3664IBA 01/2019 - 05/2018
2	Membrane Proteins (Integral Membrane Proteins)IBA 11/2017 - 03/2003
2	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2015 - 11/2015
2	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2015 - 10/2005
2	AdiponectinIBA 05/2015 - 05/2013
2	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 05/2013 - 02/2011
2	LipopolysaccharidesIBA 01/2013 - 01/2012
2	Interleukin-6 (Interleukin 6)IBA 01/2013 - 01/2012
2	RNA Splicing FactorsIBA 03/2012 - 08/2011
2	alkylglycerophosphoethanolamine phosphodiesteraseIBA 01/2012 - 03/2009
2	Phosphatidic Acids (Phosphatidic Acid)IBA 02/2011 - 03/2003
1	CarbohydratesIBA 05/2024

Therapy/Procedure

6	Therapeutics 01/2021 - 03/2003
4	Drug Therapy (Chemotherapy) 05/2023 - 03/2003
2	Platelet Transfusion (Blood Platelet Transfusions) 01/2021 - 01/2013